⌕
Lilly(Eli) · LLY · NYSE
Tenet 49 · Mixed
Compare
$1,443.50+1.14%At closeTenet 49 · Mixed
$1,443.50+16.22 (+1.14%)
At close: Nov 13, 2026, 4:00 PM ET· NYSE · USD
$1,433.48
After hours: Nov 16, 2026, 6:02 PM ET

Lilly(Eli) (LLY) Stock

Lilly(Eli) (LLY) closed at $1,443.50 on Nov 13, 2026; its Tenet Score is 49 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$1,443.50
Nov 13, 2026
Market cap
$1.29T
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
46.8×
price ÷ earnings
Dividend yield
0.48%
past year's regular dividends ÷ price
52-week range
850.51 – 1460.00
low → high · as of close, Nov 13, 2026
Tenet Score
49/100
Mixed · 313 Healthcare peers

Industry: Drugs

Lilly(Eli) & Co scores 49/100. Mixed. Strongest on growth and quality, value is the soft spot, trading at 47× earnings versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
49/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
18
Quality
78
Health
21
Growth
80

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityBHealthFGrowthBMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
32.1×
price to book value
P/S
14.9×
price to fiscal 2025 sales
ROE
86%
return on equity
Operating margin
40.4%
fiscal 2025, before interest and tax
Net margin
31.9%
of revenue kept
Current ratio
1.39
current assets to liabilities
Net debt / EBITDA
1.2×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Lilly(Eli) & Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humu…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 590 US ETFs · top wrappers by weightSee all ETFs holding LLY →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

CompanyTenet ScoreMarket cap
Johnson & JohnsonJNJ48$687.9B
Abbvie IncABBV42$521.5B
Merck & Co IncMRK41$364.3B
Novartis AGNVS56$306.3B
AMGEN Inc.AMGN47$251.9B
Gilead Sciences, Inc.GILD37$208.5B
Novo NordiskNVO63$185.9B
Pfizer Inc.PFE50$164.7B
Vertex Pharmaceuticals, Inc.VRTX55$136.6B
Bristol-Myers Squibb Co.BMY51$129.7B

Compare Lilly(Eli) with

What sector and industry is Lilly(Eli) in?

Lilly(Eli) is in the Healthcare sector and the Drugs industry.

What is Lilly(Eli)'s Tenet Score?

Lilly(Eli)'s Tenet Score is 49 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.